De Novo Genome Assembly Global Market Report 2026

The de novo genome assembly market size has grown rapidly in recent years. It will grow from $1.99 billion in 2025 to $2.28 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing use of next-generation sequencing, growth of academic research initiatives, adoption of genome assembly software, rising demand in clinical diagnostics, development of plant and microbial genomics projects.

The de novo genome assembly market size is expected to see rapid growth in the next few years. It will grow to $3.96 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to integration of ai in genome assembly, expansion of cloud-based bioinformatics platforms, demand for rapid custom genome sequencing, growth in precision medicine applications, investment in evolutionary and environmental genomics. Major trends in the forecast period include automated genome assembly pipelines, cloud-based data analysis, high-throughput sequencing integration, custom bioinformatics services, visualization & annotation enhancements.

The increasing demand for personalized medicine is anticipated to drive the expansion of the de novo genome assembly market in the coming years. Personalized medicine involves medical treatments and therapies specifically tailored to individual patients based on their genetic profile, biomarkers, and distinct disease characteristics. This demand is rising owing to advancements in genomic technologies and molecular diagnostics, which allow treatments to be customized according to an individual’s genetic makeup, enhancing outcomes and reducing side effects. De novo genome assembly supports personalized medicine by reconstructing an individual’s genome from the ground up, facilitating the identification of unique genetic variants and structural changes that guide precision therapies, customized drug selection, and early disease intervention. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022, including seven cancer therapies and three for other diseases and conditions. Consequently, the rising demand for personalized medicine is propelling the growth of the de novo genome assembly market.

Leading companies operating in the de novo genome assembly market are focusing on developing innovative solutions such as high-throughput genome assembly platforms to accelerate genome reconstruction and improve accuracy for complex and diverse organisms. High-throughput genome assembly platforms are advanced systems that combine long- and short-read sequencing data to rapidly reconstruct complete genomes with high precision, enabling researchers to generate contiguous assemblies faster and manage complex or repetitive genomic regions more efficiently than traditional methods. For example, in May 2024, Dovetail Genomics Inc., a US-based genomics technology company, introduced the AssemblyLINK Assay, a high-throughput genome assembly platform designed to accelerate genome assembly workflows and enhance the accuracy of de novo assemblies. The AssemblyLINK Assay integrates proprietary scaffolding technology with existing sequencing data to produce highly contiguous genome assemblies, simplifies data processing through streamlined computational pipelines, and supports a wide range of organisms, from plants and animals to microbial communities. Its distinctive features include compatibility with multiple sequencing platforms, reduction in manual intervention, and optimized performance for complex and large genomes, making it particularly valuable for biodiversity research and conservation genomics.

In May 2024, MedGenome Labs Pvt. Ltd., an India-based genomics and molecular diagnostics company focused on delivering de novo genome assembly services, formed a partnership with Pacific Biosciences of California Inc. (PacBio) to assist researchers in producing high-quality reference genomes and advancing genomic studies. Through this collaboration, MedGenome Labs Pvt. Ltd. and PacBio aim to aid researchers in generating top-tier reference genomes, promoting multiomics research, enabling thorough analysis of complex genomic regions, supporting the discovery of novel genes and regulatory elements, and speeding up the development of precision medicine and biotechnological innovations. Pacific Biosciences of California Inc. is a US-based company specializing in long-read DNA sequencing and genomic analysis platforms.

Major companies operating in the de novo genome assembly market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, Illumina Inc., QIAGEN N.V., Novogene Corporation, Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Medgenome labs pvt. Ltd, DNASTAR Inc., Nucleome Informatics Pvt Ltd, Seven Bridges Genomics, DNAnexus Inc., Strand Life Sciences Pvt. Ltd., BaseClear B.V., Dovetail Genomics LLC, SoftGenetics LLC, CosmosID Inc., Microba Life Sciences Ltd., GenomeScan B.V., BGI Genomics Co. Ltd., Macrogen Inc., SeqMatic LLC, NeuGen Biologicals.

North America was the largest region in the de novo genome assembly market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the de novo genome assembly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the de novo genome assembly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The de novo genome assembly market includes revenues earned by entities by service such as genome assembly sequencing, bioinformatics analysis, genome annotation, custom genome assembly, comparative genomics analysis, structural variant analysis, metagenome assembly, microbial genome assembly, plant genome assembly and animal genome assembly. The market value includes the value of related goods sold by the service provider or included within the service offering. The de novo genome assembly market also includes sales of sequencing instruments, library preparation kits, reagents, flow cells, sequencing chips, sample preparation systems, high performance computing servers, storage systems, genome assembly software packages. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

De novo genome assembly is the method of reconstructing a complete genome sequence from short DNA fragments without referencing an existing genome. It relies on overlapping sequences between fragments to accurately assemble the original genome. This technique is critical for studying organisms with unknown or highly variable genomes.

The essential components of de novo genome assembly include software and services. Software refers to bioinformatics tools that reconstruct genomes from sequencing data without relying on a reference genome, enabling analysis of novel or poorly characterized organisms. Organism types include human, animal, plant, microbial, and metagenomic or mixed samples, and technologies utilized include next-generation sequencing, third-generation sequencing, Sanger sequencing, and others. Applications include clinical diagnostics, agricultural genomics, environmental genomics, evolutionary biology, and more, serving academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and other end-users.

Tariffs have affected the de novo genome assembly market by increasing costs for importing advanced sequencing instruments, software tools, and reagents. Segments such as software and sequencing services are most impacted, particularly in regions like North America and Europe that depend on imported high-end sequencing technologies. While tariffs may slow adoption temporarily, they are encouraging local manufacturing, fostering development of cost-effective sequencing solutions, and driving innovation in genome assembly services.

The de novo genome assembly market research report is one of a series of new reports that provides de novo genome assembly market statistics, including de novo genome assembly industry global market size, regional shares, competitors with a de novo genome assembly market share, detailed de novo genome assembly market segments, market trends and opportunities, and any further data you may need to thrive in the de novo genome assembly industry. This de novo genome assembly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.